INmune Bio (INMB) Stock Price, News & Analysis

Company Overview

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Key Stats

• Today's Range: $2.04 to $2.15
• 50-Day Range: $2.05 to $7.37
• 52-Week Range: $1.89 to $11.64
• Volume: 518,999 shs
• Average Volume: 1.54 million shs
• Market Capitalization: $55.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.40
• Consensus Rating: Moderate Buy

INmune Bio Stock Analysis - MarketRank™

INmune Bio scored higher than 40% of companies evaluated by MarketBeat, and ranked 709th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

INmune Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 3 buy ratings, 2 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

INmune Bio has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for INmune Bio are expected to grow in the coming year, from ($2.24) to ($1.54) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of INmune Bio is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of INmune Bio is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

INmune Bio has a P/B Ratio of 1.92. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

34.98% of the float of INmune Bio has been sold short.

Short Interest Ratio / Days to Cover

INmune Bio has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in INmune Bio has recently increased by 8.14%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

INmune Bio does not currently pay a dividend.

Dividend Growth

INmune Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

34.98% of the float of INmune Bio has been sold short.

Short Interest Ratio / Days to Cover

INmune Bio has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in INmune Bio has recently increased by 8.14%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: 1.07

News Sentiment

INmune Bio has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for INmune Bio this week, compared to 3 articles on an average week.

Search Interest

Only 8 people have searched for INMB on MarketBeat in the last 30 days. This is a decrease of -68% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added INmune Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, INmune Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

35.70% of the stock of INmune Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 12.72% of the stock of INmune Bio is held by institutions.

INMB Stock Analysis - Frequently Asked Questions

How have INMB shares performed this year?

INmune Bio's stock was trading at $4.67 at the start of the year. Since then, INMB stock has decreased by 55.1% and is now trading at $2.0950.

How were INmune Bio's earnings last quarter?

INmune Bio, Inc. (NASDAQ:INMB) announced its earnings results on Thursday, August, 7th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.03.
Read the conference call transcript.

Who are INmune Bio's major shareholders?

Top institutional investors of INmune Bio include Sio Capital Management LLC, Rosalind Advisors Inc., Caption Management LLC and Geode Capital Management LLC (1.65%). Insiders that own company stock include Raymond Joseph Tesi, David J Moss, Timothy J Schroeder and Scott Juda.
View institutional ownership trends.

How do I buy shares of INmune Bio?

Shares of INMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of INmune Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that INmune Bio investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), ServiceNow (NOW) and Netflix (NFLX).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 8/28/2025
• Next Earnings (Estimated): 10/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:INMB
• CIK: 1711754
• Web: www.inmunebio.com
• Phone: (858) 964-3720
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Price Target for INmune Bio: $18.40
• High Price Target: $23.00
• Low Price Target: $8.00
• Potential Upside/Downside: +797.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.57
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.48)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$42.08 million
• Net Margins: N/A
• Pretax Margin: -111,016.00%
• Return on Equity: -120.62%
• Return on Assets: -92.94%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.20
• Quick Ratio: 4.20

Sales & Book Value

• Annual Sales: $10 thousand
• Price / Sales: 5,448.90
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.09 per share
• Price / Book: 1.88

Miscellaneous

• Outstanding Shares: 26,580,000
• Free Float: 17,094,000
• Market Cap: $54.49 million
• Optionable: Optionable
• Beta: 0.97